Your browser doesn't support javascript.
loading
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
Rizzari, Carmelo; Lanvers-Kaminsky, Claudia; Valsecchi, Maria Grazia; Ballerini, Andrea; Matteo, Cristina; Gerss, Joachim; Wuerthwein, Gudrun; Silvestri, Daniela; Colombini, Antonella; Conter, Valentino; Biondi, Andrea; Schrappe, Martin; Moericke, Anja; Zimmermann, Martin; von Stackelberg, Arend; Linderkamp, Christin; Frühwald, Michael C; Legien, Sabine; Attarbaschi, Andishe; Reismüller, Bettina; Kasper, David; Smisek, Petr; Stary, Jan; Vinti, Luciana; Barisone, Elena; Parasole, Rosanna; Micalizzi, Concetta; Zucchetti, Massimo; Boos, Joachim.
Affiliation
  • Rizzari C; Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy c.rizzari@asst-monza.it.
  • Lanvers-Kaminsky C; Department of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.
  • Valsecchi MG; Medical Statistics Unit, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy.
  • Ballerini A; Department of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Matteo C; Department of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Gerss J; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
  • Wuerthwein G; Department of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.
  • Silvestri D; Medical Statistics Unit, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy.
  • Colombini A; Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.
  • Conter V; Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.
  • Biondi A; Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.
  • Schrappe M; Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Moericke A; Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Zimmermann M; Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
  • von Stackelberg A; Pediatric Hematology and Oncology, Charité, Berlin, Germany.
  • Linderkamp C; Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
  • Frühwald MC; Children's Hospital, Augsburg, Germany.
  • Legien S; Pediatrics 5 (Oncology, Hematology, Immunology); Stuttgart Cancer Center; Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
  • Attarbaschi A; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
  • Reismüller B; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
  • Kasper D; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Smisek P; Czech Paediatric Haematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Stary J; Czech Paediatric Haematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Vinti L; Department of Pediatric Hemato-Oncology, Ospedale Bambino Gesù, Rome, Italy.
  • Barisone E; Department of Pediatric Hemato-Oncology, Regina Margherita Children's Hospital, Turin, Italy.
  • Parasole R; Department of Pediatric Hematology-Oncology, Ospedale Pausillipon, Naples, Italy.
  • Micalizzi C; Department of Pediatric Hematology-Oncology, IRCCS I.G. Gaslini, Genova, Italy.
  • Zucchetti M; Department of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Boos J; Department of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.
Haematologica ; 104(9): 1812-1821, 2019 09.
Article in En | MEDLINE | ID: mdl-30705097
Asparagine levels in cerebrospinal fluid and serum asparaginase activity were monitored in children with acute lymphoblastic leukemia treated with pegylated-asparaginase. The drug was given intravenously at a dose of 2,500 IU/m2 on days 12 and 26. Serum and cerebrospinal fluid samples obtained on days 33 and 45 were analyzed centrally. Since physiological levels of asparagine in the cerebrospinal fluid of children and adolescents are 4-10 µmol/L, in this study asparagine depletion was considered complete when the concentration of asparagine was ≤0.2 µmol/L, i.e. below the lower limit of quantification of the assay used. Over 24 months 736 patients (AIEOP n=245, BFM n=491) and 903 cerebrospinal fluid samples (n=686 on day 33 and n=217 on day 45) were available for analysis. Data were analyzed separately for the AIEOP and BFM cohorts and yielded superimposable results. Independently of serum asparaginase activity levels, cerebrospinal fluid asparagine levels were significantly reduced during the investigated study phase but only 28% of analyzed samples showed complete asparagine depletion while relevant levels, ≥1 µmol/L, were still detectable in around 23% of them. Complete cerebrospinal fluid asparagine depletion was found in around 5-6% and 33-37% of samples at serum asparaginase activity levels <100 and ≥ 1,500 IU/L, respectively. In this study cerebrospinal fluid asparagine levels were reduced during pegylated-asparaginase treatment, but complete depletion was only observed in a minority of patients. No clear threshold of serum pegylated-asparaginase activity level resulting in complete cerebrospinal fluid asparagine depletion was identified. The consistency of the results found in the two independent data sets strengthen the observations of this study. Details of the treatment are available in the European Clinical Trials Database at https://www.clin-icaltrialsregister.eu/ctr-search/trial/2007-004270-43/IT.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polyethylene Glycols / Asparaginase / Asparagine / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Clinical_trials Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Europa Language: En Journal: Haematologica Year: 2019 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polyethylene Glycols / Asparaginase / Asparagine / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Clinical_trials Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Europa Language: En Journal: Haematologica Year: 2019 Document type: Article Affiliation country: Country of publication: